Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience

Vincenzo Russo; Emilio Attena; Carmine Mazzone; Francesca Esposito; Valentina Parisi; Ciro Bancone; Anna Rago; Gerardo Nigro; Raffaele Sangiuolo; Antonio D' Onofrio

doi:10.1055/s-0037-1615261

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2018; 44(04): 364-369
DOI: 10.1055/s-0037-1615261

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience

Vincenzo Russo

¹Chair of Cardiology, University of Campania “Luigi Vanvitelli,” Monaldi Hospital, Naples, Italy

,

Emilio Attena

²Department of Cardiology, Fatebenefratelli Hospital, Naples, Italy

,

Carmine Mazzone

³Cardiovascular Centre, Health Authority 1, Trieste, Italy

,

Francesca Esposito

⁴Department of Cardiology, San Giovanni di Dio e Ruggi d'Aragona Hospital, Salerno, Italy

,

Valentina Parisi

⁵Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy

,

Ciro Bancone

⁶Cardiac Surgery Unit, Monaldi Hospital, Naples, Italy

,

Anna Rago

¹Chair of Cardiology, University of Campania “Luigi Vanvitelli,” Monaldi Hospital, Naples, Italy

,

Gerardo Nigro

¹Chair of Cardiology, University of Campania “Luigi Vanvitelli,” Monaldi Hospital, Naples, Italy

,

Raffaele Sangiuolo

²Department of Cardiology, Fatebenefratelli Hospital, Naples, Italy

,

Antonio D' Onofrio

⁷Departmental Unit of Electrophysiology, Evaluation and Treatment of Arrhythmias, Monaldi Hospital, Naples, Italy

› Institutsangaben

Abstract

This is an observational study to investigate the efficacy and safety of nonvitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with bioprosthetic valves or prior surgical valve repair in clinical practice. A total of 122 patients (mean age: 74.1 ± 13.2; 54 females) with bioprosthetic heart valve or surgical valve repair and AF treated with NOACs were included in the analysis. The mean CHA₂DS₂-VASc (Congestive heart failure, Hypertension, Age >75 years, Diabetes mellitus, prior Stroke or transient ischemic attack, Vascular disease) and HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INR [international normalized ratio], Elderly, Drugs or alcohol) score values were 3.6 ± 1.2 and 2.6 ± 1.4, respectively. Of the total study population, 28.6% was taking apixaban 5 mg twice daily (BID), 24.5% apixaban 2.5 mg BID, 18% dabigatran 150 mg BID, 13% dabigatran 110 mg BID, 9.8% rivaroxaban 20 mg daily (QD), and 5.7% rivaroxaban 15 mg QD. Also, 92% of the study population previously had warfarin replaced with NOACs due to lack compliance and labile INR control (time in therapeutic range < 60%). NOAC therapy for AF was started on average 934 ± 567 days after bioprosthetic heart valve implantation or surgical repair for an average duration of 835 ± 203 days. The study population included 24 (19.6%) patients with bioprosthetic mitral valve, 52 (43%) patients with bioprosthetic aortic valve, 41 (33.6%) patients with previous surgical mitral repair, 5 (4%) patients with previous surgical aortic repair, and concomitant use of NOACs. All patients were evaluated for thromboembolic events (ischemic stroke, transient ischemic attack, systemic embolism) as well as major bleeding events during the follow-up period. In our study population, we recorded a low mean annual incidence of thromboembolism (0.8%) and major bleeding (1.3%). According to our data, anticoagulation therapy with NOACs seems to be an effective and a safe treatment strategy for nonvalvular AF patients with bioprosthetic valves or prior surgical valve repair.

Keywords

atrial fibrillation - bioprosthetic valve - surgical valve repair - NOACs - dabigatran - apixaban - rivaroxaban - stroke - major bleedings

Volltext

Referenzen

References
1 Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368 (9540): 1005-1011
2 Isaacs AJ, Shuhaiber J, Salemi A, Isom OW, Sedrakyan A. National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements. J Thorac Cardiovasc Surg 2015; 149 (05) 1262-9.e3
3 Russo V, Rago A, Proietti R. , et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf 2017; 8 (02) 67-75
4 January CT, Wann LS, Alpert JS. , et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130 (23) 2071-2104
5 Kirchhof P, Benussi S, Kotecha D. , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18 (11) 1609-1678
6 Heidbuchel H, Verhamme P, Alings M. , et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17 (10) 1467-1507
7 Patel MR, Mahaffey KW, Garg J. , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
8 Granger CB, Alexander JH, McMurray JJ. , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
9 Giugliano RP, Ruff CT, Braunwald E. , et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
10 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
11 Yadlapati A, Groh C, Malaisrie SC. , et al. Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves. Clin Res Cardiol 2016; 105 (03) 268-272
12 Di Biase L, Trivedi C, Mohanty P. , et al. Periprocedural and long term safety and feasibility of treatment with novel oral anticoagulants in patients with biological valve and atrial fibrillation. Presented at the American College of Cardiology 64th Annual Scientific Session [P-255]; March 14–16, 2015, San Diego, CA
13 Connolly SJ, Ezekowitz MD, Yusuf S. , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
14 Breithardt G, Baumgartner H, Berkowitz SD. , et al; ROCKET AF Steering Committee & Investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014; 35 (47) 3377-3385
15 Avezum A, Lopes RD, Schulte PJ. , et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation 2015; 132 (08) 624-632
16 Carnicelli AP, De Caterina R, Halperin JL. , et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation 2017; 135 (13) 1273-1275
17 Durães AR, de Souza Roriz P, de Almeida Nunes B. , et al. Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study. Drugs R D 2016; 16 (02) 149-154
18 Russo V, Bianchi V, Cavallaro C. , et al. Efficacy and safety of dabigatran in a “real-life” population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry. Eur Rev Med Pharmacol Sci 2015; 19 (20) 3961-3967
19 Russo V, Di Napoli L, Bianchi V. , et al. A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: the MonaldiVert real life experience. Int J Cardiol 2016; 224: 454-455